Cellectis announced the operational withdrawal of Frederic Paques, who has joined the Group's Scientific Advisory Board, as well as three appointments in its Scientific Division: Jean-Charles Epinat as Chief Technology Officer, Philippe Duchateau as Chief Scientific Officer, and Frederic Cedrone as Platform Director. Jean-Charles Epinat has been appointed as Cellectis' Chief Technology Officer, joining the Company's executive committee. With a PhD in science, he carried out his postdoctoral fellowship at Boston University (Massachusetts, USA), before moving to the Institut Pasteur. Philippe Duchateau has been appointed Chief Scientific Officer. With a PhD in science, Philippe Duchateau joined Cellectis in 2001 after nine years with the University of California's Cardiovascular Research Institute (San Francisco, USA). Frederic Paques, who graduated from Ecole Normale Superieure de Paris and has a PhD in science, began his career at Brandeis University (Massachusetts, USA), before joining the CNRS' (Paris) Institut Jacques Monod in 1999. Appointed as Cellectis' Chief Scientific Officer in 2002, Frederic Paques has been behind the design and deployment of the mass screening tools which have made a key contribution towards Cellectis' scientific success.